GTX-RT in Borderline Resectable Pancreatic Cancer

Inclusion Criteria

• •Patients must have histologically or cytologically confirmed pancreatic adenocarcinoma that is borderline resectable disease. Borderline resectable lesions are defined as:
• •* circumferential tumor abutment with the superior mesenteric vein (SMV) or portal vein (PV) or SMV/PV confluence over \</= 180°
• •* circumferential tumor abutment with the superior mesenteric artery (SMA) over \</= 180°
• •* Short segment encasement (360°) of the PV or SMV that is amenable to partial vein resection and reconstruction
• •* encasement of the gastroduodenal artery up to the origin of the hepatic artery
• •Patients must have measurable disease
• •No previous chemotherapy or radiation to the pancreas
• •Eastern Cooperative Oncology Group (ECOG) performance status \</= 2 (Karnofsky \>/= 60%)
• •Patients must have normal organ and marrow function as defined below:
• •* leukocytes \>/= 3,000/μL
• •* absolute neutrophil count \>/= 1,000/ μL
• •* platelets \>/= 100,000/ μL
• •* creatinine within normal institutional limits (ULN)
• •* total bilirubin will allow for 2x the upper limit of the institution. Patients may have biliary stents or drains to lower total bilirubin to this range.
• •Has a negative serum or urine pregnancy test within 7 days prior to initiation of therapy (female patients of childbearing potential). Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Patients will agree to continue contraception for 30 days from the date of the last study drug administration.
• •Ability to understand and the willingness to sign a written informed consent document